Cambrex Invests in US R&D Facility
Cambrex is investing in a new R&D facility in Minneapolis, Minnesota, USA, expanding its capacity for small molecule development and manufacturing.
The new facility will specialize in analytical and chemical development for pharmaceutical drug candidates and will operate as an extension of Cambrex’s flagship facility in Charles City, Iowa. The company expects to add about 40 new jobs over the next two-to-three years at the Minneapolis site.
“Our new facility in Minneapolis will double our analytical and chemical development footprint in the Midwest, providing clients with easy access to state-of-the-art capabilities and top scientific experts. We continue to invest in our US-based footprint to support the demand for high-quality API development and manufacturing,” said CEO Thomas Loewald
At the same time, Cambrex will launch a multi-phase expansion and renovation project at its Charles City site. The project will add a new quality control laboratory and administrative office space, modernizing the existing quality control and R&D facilities, and creating 40 new jobs.
This investment follows an earlier $50 million expansion at Charles City that was completed in the first quarter of 2022, expanding API capacity by 30%. The facility produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.
Cambrex also completed in September the first phase of a $30 million investment in small-scale API manufacturing facility in High Point, North Carolina. The second phase of the project is ongoing and will roughly double the facility’s capacity.
Another expansion is currently under way for small- and mid-scale API manufacture in Karlskoga, Sweden, where the extra capacity is expected to come online in mid-2023.
Author: Elaine Burridge, Freelance Journalist
